Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Bullboard (NDAQ:GRCE)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Post by Francine01on Jan 21, 2021 10:46am

Over 140M share traded today !!

Any clue what is going on ?: - merger - financing round is coming - starting OM3 natural product line  - somone is buying the company.  - manipulation to avoid the Nasdaq delisting  ...more  
343
Discussion
Post by Super63on Jan 16, 2021 3:31pm

Dr Merette

Anyone know if the study with him is still ongoing. Would not make sense to release endpoint data from Tril without combining with any ongoing study on Capre     Thoughts?
273
Post by Super63on Jan 16, 2021 11:25am

don't be short when this patent drops

Dr. Marette commented, “Our initial pre-clinical studies with CaPre are very promising. The effect of CaPre on insulin secretion may suggest preservation of beta-cell function early in the development ...more  
303
Comment by Super63on Jan 15, 2021 4:39pm

RE:RE:RE:RE:9 billion

So important for me to understand this point concerning endpoint data.  The value is in the lowering of A1C which the Pfizer chair study on mice suggested was promising.  If true, won't ...more  
211
Discussion
Comment by Normandt1965on Jan 15, 2021 11:49am

RE:RE:9 billion

Very interesting. https://lipidworld.biomedcentral.com/articles/10.1186/s12944-017-0601-8
179
Discussion
Comment by EternalPonzion Jan 15, 2021 11:15am

RE:RE:RE:9 billion

Negative, no short. No skin in this game anymore. I was very tempted to though when I saw it climb to over $1 so quickly. It was 100% guaranteed to pull back regardless of headline risk. On that topic ...more  
198
Discussion
Comment by Normandt1965on Jan 15, 2021 11:14am

RE:RE:9 billion

Asian market is huge, I'm very confident.
113
Discussion
Comment by Super63on Jan 14, 2021 5:19pm

RE:RE:9 billion

You make some good points. Your knowledge of the French site gives you credibility. First, why are you still here? Short? I would not think so as you must be aware of headline risk sending this up ...more  
173
Discussion
Comment by EternalPonzion Jan 14, 2021 10:21am

RE:9 billion

That may or may not be true. The important fact is any product must be able to compete. If I am not mistaken, I believe CaPre is a relatively expensive supplement to manufacture and for now a company ...more  
180
Discussion
Comment by Francine01on Jan 13, 2021 3:00pm

RE:9 billion

No clue who could be the buyer or shareholder of control of Acasti. But Yes, it could come from the Asian market. Remember in November 2017, Acasti signed a agreement with a Chinese pharma. Asian ...more  
244
Discussion
Post by Super63on Jan 12, 2021 7:00pm

9 billion

China is strategically important for Aker BioMarine to grow within its Ingredients segment. According to the latest GOED (The Global Organization for EPA and DHA Omega-3s) industry report, China’s ...more  
284
Discussion
Comment by Super63on Jan 12, 2021 4:41pm

RE:RE:RE:RE:Hi Francine

Everyone should simply endeavour to eat healthy and exercise. Yes there are some people who are genetically predisposed to high TG levels but that is a very small proportion of the population. Most ...more  
173
Discussion
Comment by EternalPonzion Jan 12, 2021 12:20pm

RE:RE:RE:Hi Francine

Sorry Francine, I don't buy it. Full disclosure. I sold and took loss ages ago. If you hung on good for you but now you have been given a second chance to unload - take it especially for those who ...more  
213
Discussion
Post by Super63on Jan 11, 2021 6:22pm

Thank you Francine

Did you see Eddingpharm completed hi- tri study for Vascepa in China?  They only released top line result, no details on placebo etc..    My merger candidates are Eddingpharm, Aker ...more  
220
Comment by rapido75on Jan 11, 2021 12:25pm

RE:RE:Hi Francine

Forget Francine, whoever he/she/it is.This is the second time in as many weeks that there has been a huge spike on high volume. Surely the company has some info on what is causing this.
177
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities